#The American College of Cardiology and American Heart Association developed a classification of heart failure based on stages of the syndrome..
#(S1 (S (NP (NP (DT The) (NNP American) (NNP College)) (PP (IN of) (NP (NNP Cardiology) (CC and) (NNP American) (NNP Heart) (NNP Association)))) (VP (VBD developed) (NP (NP (DT a) (NN classification)) (PP (IN of) (NP (NN heart) (NN failure))) (VP (VBN based) (PP (IN on) (NP (NP (NNS stages)) (PP (IN of) (NP (DT the) (NN syndrome)))))) (. .))) (. .)))
#Rule:Nouns
r1American College of CardiologyOrganizationAnnotation
r1American Heart AssociationOrganizationAnnotation
r1classificationNN
r1heartNN
r1failureNN
r1stagesNNS
r1syndromeNN

#Rule:Verbs
r2developedVBD
r2basedVBN

#Rule:N-HeadNoun
r8heartNNfailureNN

#Rule:HeadNoun-V
r11American College of CardiologyOrganizationAnnotationdevelopedVBD

#Rule:V-HeadNoun
r21developedVBDclassificationNN

#Rule:V-HeadNoun(passive)
r24basedVBNclassificationNN

#Rule:PPinNP
r26classificationNNofINfailureNN
r26stagesNNSofINsyndromeNN

#Rule:PPinVP
r32basedVBNonINstagesNNS

#Stage 1 includes patients at risk of developing heart failure but who have no structural heart disease at present. These include patients with hypertension, diabetes mellitus, coronary artery disease, use of cardiac toxins, and familial history of cardiomyopathy. Strategies to prevent ventricular remodeling, including ACE inhibitors in selected cases, are advised. Stage 2 includes patients with structural heart disease but no symptoms. The use of ACE inhibitors and beta-blockers is recommended..
#(S1 (S (NP (NN Stage) (CD 1)) (VP (VBZ includes) (NP (NP (NNS patients)) (PP (IN at) (NP (NP (NN risk)) (PP (IN of) (S (VP (VBG developing) (NP (NN heart) (NN failure)) (FRAG (CC but) (SBAR (WHNP (WP who)) (S (VP (AUX have) (NP (DT no) (JJ structural) (NN heart) (NN disease)) (PP (IN at) (NP (NP (NN present.)) (SBAR (S (NP (DT These)) (VP (VBP include) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (NN hypertension)) (, ,) (NP (NN diabetes) (NN mellitus)) (, ,) (NP (JJ coronary) (NN artery) (NN disease)) (, ,) (NP (NP (NN use)) (PP (IN of) (NP (JJ cardiac) (NNS toxins)))) (, ,) (CC and) (NP (NP (JJ familial) (NN history)) (PP (IN of) (NP (NP (JJ cardiomyopathy.) (NNS Strategies)) (SBAR (S (VP (TO to) (VP (VB prevent) (SBAR (S (NP (JJ ventricular) (NN remodeling)) (, ,) (PP (VBG including) (NP (NP (NN ACE) (NNS inhibitors)) (PP (IN in) (NP (JJ selected) (NNS cases))))) (, ,) (VP (AUX are) (VP (VBN advised.) (NP (NNP Stage) (CD 2)) (SBAR (S (VP (VBZ includes) (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ structural) (NN heart) (NN disease)) (CC but) (NP (NP (DT no) (NN symptoms.)) (SBAR (S (NP (NP (DT The) (NN use)) (PP (IN of) (NP (NNP ACE) (NNS inhibitors) (CC and) (NNS beta-blockers)))) (VP (AUX is) (VP (VBN recommended)))))))))))))))))))))))))))))))))) (. .))))))))) (. .)))
#Rule:Nouns
r1StageNN
r1patientsNNS
r1riskNN
r1heartNN
r1failureNN
r1heartNN
r1diseaseNN
r1presentNN
r1patientsNNS
r1hypertensionNN
r1diabetesNN
r1mellitusNN
r1arteryNN
r1diseaseNN
r1useNN
r1toxinsNNS
r1historyNN
r1StrategiesNNS
r1remodelingNN
r1ACENN
r1inhibitorsNNS
r1casesNNS
r1StageNNP
r1patientsNNS
r1heartNN
r1diseaseNN
r1symptomsNN
r1useNN
r1ACENNP
r1inhibitorsNNS
r1beta-blockersNNS

#Rule:Verbs
r2includesVBZ
r2developingVBG
r2includeVBP
r2preventVB
r2includingVBG
r2advisedVBN
r2includesVBZ
r2recommendedVBN

#Rule:Adjs
r4structuralJJ
r4coronaryJJ
r4cardiacJJ
r4familialJJ
r4cardiomyopathyJJ
r4ventricularJJ
r4selectedJJ
r4structuralJJ

#Rule:Adj-Noun
r51CDStageNN
r5structuralJJdiseaseNN
r5coronaryJJdiseaseNN
r5cardiacJJtoxinsNNS
r5familialJJhistoryNN
r5cardiomyopathyJJStrategiesNNS
r5ventricularJJremodelingNN
r5selectedJJcasesNNS
r52CDStageNNP
r5structuralJJdiseaseNN

#Rule:N-HeadNoun
r8heartNNfailureNN
r8heartNNdiseaseNN
r8diabetesNNmellitusNN
r8arteryNNdiseaseNN
r8ACENNinhibitorsNNS
r8heartNNdiseaseNN
r8ACENNPinhibitorsNNS

#Rule:N-ApposN
r10hypertensionNNmellitusNN

#Rule:HeadNoun-V
r11StageNNincludesVBZ
r11theseDTincludeVBP

#Rule:HeadNoun-(who/that)-V
r14StrategiesNNSpreventVB

#Rule:NP(NP(z) SBAR(S(NP(x)VP(y))))
r19recommendedVBNsymptomsNN

#Rule:V-HeadNoun
r21includesVBZpatientsNNS
r21developingVBGfailureNN
r21haveAUXdiseaseNN
r21includeVBPpatientsNNS
r21advisedVBNStageNNP
r21includesVBZpatientsNNS

#Rule:V-HeadNoun(passive)
r23advisedVBNremodelingNN
r23recommendedVBNuseNN

#Rule:PPinNP
r26patientsNNSatINriskNN
r26patientsNNSwithINhypertensionNN
r26patientsNNSwithINmellitusNN
r26patientsNNSwithINdiseaseNN
r26patientsNNSwithINuseNN
r26patientsNNSwithINhistoryNN
r26useNNofINtoxinsNNS
r26historyNNofINStrategiesNNS
r26inhibitorsNNSinINcasesNNS
r26patientsNNSwithINdiseaseNN
r26patientsNNSwithINsymptomsNN
r26useNNofINinhibitorsNNS

#Rule:PPinVP
r30haveAUXatINpresentNN

#Stage 3 includes patients with structural heart disease and symptomatic heart failure. Diuretics, digoxin, and aldosterone antagonists may be added to ACE inhibitors and beta-blockers depending upon the severity of symptoms. Cardiac resynchronization therapy also may be considered in selected patients. Stage 4 includes patients with severe refractory heart failure. Physicians are urged to consider either end-of-life care or high-tech therapies such as cardiac transplantation, based on individual cases..
#(S1 (S (NP (NN Stage) (CD 3)) (VP (VBZ includes) (SBAR (S (S (NP (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ structural) (NN heart) (NN disease)) (CC and) (NP (JJ symptomatic) (NN heart)))) (PP (FW failure.) (NP (NNP Diuretics)))) (, ,) (NP (NN digoxin)) (, ,) (CC and) (NP (JJ aldosterone) (NNS antagonists))) (VP (MD may) (VP (AUX be) (VP (VBN added) (PP (TO to) (NP (NNP ACE) (NNS inhibitors))))))) (CC and) (S (NP (NP (NNS beta-blockers)) (PP (VBG depending) (PP (IN upon) (NP (NP (DT the) (NN severity)) (PP (IN of) (NP (JJ symptoms.) (NNP Cardiac) (NN resynchronization) (NN therapy))))))) (ADVP (RB also)) (VP (MD may) (VP (AUX be) (VP (VBN considered) (PP (IN in) (NP (NP (VBN selected) (JJ patients.) (NN Stage)) (SBAR (WHNP (CD 4)) (S (VP (VBZ includes) (SBAR (S (NP (NP (NNS patients)) (PP (IN with) (NP (NP (JJ severe) (JJ refractory) (NN heart)) (PP (FW failure.) (NP (NNP Physicians)))))) (VP (AUX are) (VP (VBN urged) (S (VP (TO to) (VP (VB consider) (NP (NP (DT either) (JJ end-of-life) (NN care) (CC or) (JJ high-tech) (NNS therapies)) (PP (JJ such) (IN as) (NP (JJ cardiac) (NN transplantation))) (, ,) (PP (VBN based) (PP (IN on) (NP (JJ individual) (NNS cases)))))))))))))))))))) (. .))))) (. .)))
#Rule:Nouns
r1StageNN
r1patientsNNS
r1heartNN
r1diseaseNN
r1heartNN
r1DiureticsPersonAnnotation
r1digoxinLocationAnnotation
r1antagonistsNNS
r1ACENNP
r1inhibitorsNNS
r1beta-blockersNNS
r1severityNN
r1CardiacNNP
r1resynchronizationNN
r1therapyNN
r1StageNN
r1patientsNNS
r1heartNN
r1PhysiciansNNP
r1careNN
r1therapiesNNS
r1transplantationNN
r1casesNNS

#Rule:Verbs
r2includesVBZ
r2addedVBN
r2dependingVBG
r2consideredVBN
r2selectedVBN
r2includesVBZ
r2urgedVBN
r2considerVB
r2basedVBN

#Rule:Adjs
r4structuralJJ
r4symptomaticJJ
r4aldosteronePersonAnnotation
r4symptomsJJ
r4patientsJJ
r4severeJJ
r4refractoryJJ
r4end-of-lifeJJ
r4high-techJJ
r4suchJJ
r4cardiacJJ
r4individualJJ

#Rule:Adj-Noun
r53CDStageNN
r5structuralJJdiseaseNN
r5symptomaticJJheartNN
r5aldosteronePersonAnnotationantagonistsNNS
r5symptomsJJtherapyNN
r5selectedVBNStageNN
r5patientsJJStageNN
r5severeJJheartNN
r5refractoryJJheartNN
r5end-of-lifeJJtherapiesNNS
r5high-techJJtherapiesNNS
r5cardiacJJtransplantationNN
r5individualJJcasesNNS

#Rule:N-HeadNoun
r8heartNNdiseaseNN
r8ACENNPinhibitorsNNS
r8resynchronizationNNtherapyNN
r8CardiacNNPtherapyNN

#Rule:N-ApposN
r10patientsNNSdigoxinLocationAnnotation

#Rule:HeadNoun-V
r11StageNNincludesVBZ

#Rule:HeadNoun-(who/that)-V
r14StageNNincludesVBZ

#Rule:V-HeadNoun
r21considerVBtherapiesNNS

#Rule:V-HeadNoun(passive)
r23addedVBNpatientsNNS
r23addedVBNdigoxinLocationAnnotation
r23addedVBNantagonistsNNS
r23consideredVBNbeta-blockersNNS
r23urgedVBNpatientsNNS

#Rule:PPinNP
r26patientsNNSwithINdiseaseNN
r26patientsNNSwithINheartNN
r26severityNNofINtherapyNN
r26patientsNNSwithINheartNN
r26therapiesNNSasINtransplantationNN

#Rule:PPinVP
r32addedVBNtoTOinhibitorsNNS
r32consideredVBNinINStageNN

#Rule:V-V
r44urgedVBNconsiderVB

#ACC/AHA Classification of Chronic Heart FailureStageDescriptionAHigh risk for developing heart failureHypertension, diabetes mellitus, CAD, family history of cardiomyopathyBAsymptomatic heart failurePrevious MI, LV dysfunction, valvular heart diseaseCSymptomatic heart failureStructural heart disease, dyspnea and fatigue, impaired exercise toleranceDRefractory end-stage heart failureMarked symptoms at rest despite maximal medical therapyPlease also see Table1 New York Heart Association-Classification of Heart Failure. (Merck)Please note that I am not a medical professional.
#(S1 (S (NP (NP (NN ACC/AHA) (NN Classification)) (PP (IN of) (NP (JJ Chronic) (NNP Heart) (NNP FailureStageDescriptionAHigh) (NN risk))) (PP (IN for) (S (VP (VBG developing) (NP (NP (NP (NP (NN heart) (NN failureHypertension)) (, ,) (NP (NN diabetes) (NN mellitus)) (, ,) (NP (NN CAD)) (, ,) (NP (NP (NN family) (NN history)) (PP (IN of) (NP (JJ cardiomyopathyBAsymptomatic) (NN heart) (NN failurePrevious) (NNS MI)))) (, ,) (NP (CD LV) (NN dysfunction)) (, ,) (NP (NP (JJ valvular) (NN heart)) (JJ diseaseCSymptomatic) (NN heart) (NN failureStructural) (NN heart) (NN disease)) (, ,) (NP (NN dyspnea) (CC and) (NN fatigue)) (, ,)) (VBN impaired) (NN exercise) (S (NP (NP (JJ toleranceDRefractory) (JJ end-stage) (NN heart) (VBN failureMarked) (NNS symptoms)) (PP (IN at) (NP (NP (NN rest)) (PP (IN despite) (NP (JJ maximal) (JJ medical) (NN therapyPlease)))))) (ADVP (RB also)) (VP (VBP see) (NP (NP (NNP Table1) (NNP New) (NNP York) (NNP Heart) (NNP Association-Classification)) (PP (IN of) (NP (NN Heart) (NN Failure))))) (. .))) (PRN (-LRB- -LRB-) (NP (NNP Merck)) (-RRB- -RRB-))))))) (ADVP (UH Please)) (VP (VB note) (SBAR (IN that) (S (NP (PRP I)) (VP (AUX am) (RB not) (NP (DT a) (JJ medical) (NN professional)))))) (. .)))
#Rule:Nouns
r1ACC/AHANN
r1ClassificationNN
r1Chronic Heart FailureStageDescriptionAHigh riskOrganizationAnnotation
r1heartNN
r1failureHypertensionNN
r1diabetesNN
r1mellitusNN
r1CADOrganizationAnnotation
r1familyNN
r1historyNN
r1heartNN
r1failurePreviousNN
r1MINNS
r1dysfunctionNN
r1heartNN
r1heartNN
r1failureStructuralNN
r1heartNN
r1diseaseNN
r1dyspneaLocationAnnotation
r1fatigueNN
r1exerciseNN
r1heartNN
r1symptomsNNS
r1restNN
r1therapyPleaseNN
r1Table1 New York Heart AssociationOrganizationAnnotation
r1Association-ClassificationNNP
r1Heart FOrganizationAnnotation
r1MerckOrganizationAnnotation
r1professionalNN

#Rule:Verbs
r2developingVBG
r2impairedVBN
r2failuremarkedVBN
r2seeVBP
r2noteVB

#Rule:Adjs
r4cardiomyopathyBAsymptomaticJJ
r4valvularJJ
r4diseaseCSymptomaticJJ
r4toleranceDRefractoryJJ
r4end-stageJJ
r4maximalJJ
r4medicalJJ
r4medicalJJ

#Rule:Adj-Noun
r5impairedVBNexerciseNN
r5cardiomyopathyBAsymptomaticJJMINNS
r5LVLocationAnnotationdysfunctionNN
r5diseaseCSymptomaticJJdiseaseNN
r5valvularJJheartNN
r5toleranceDRefractoryJJsymptomsNNS
r5end-stageJJsymptomsNNS
r5failuremarkedVBNsymptomsNNS
r5maximalJJtherapyPleaseNN
r5medicalJJtherapyPleaseNN
r5medicalJJprofessionalNN

#Rule:N-HeadNoun
r8ACC/AHANNClassificationNN
r8heartNNfailureHypertensionNN
r8diabetesNNmellitusNN
r8familyNNhistoryNN
r8failurePreviousNNMINNS
r8heartNNMINNS
r8heartNNdiseaseNN
r8failureStructuralNNdiseaseNN
r8heartNNdiseaseNN
r8Table1 New York Heart AssociationOrganizationAnnotationAssociation-ClassificationNNP

#Rule:N-ApposN
r10failureHypertensionNNmellitusNN

#Rule:HeadNoun-V
r11ClassificationNNnoteVB
r11symptomsNNSseeVBP
r11iPRPamAUX

#Rule:V-HeadNoun
r21developingVBGexerciseNN
r21seeVBPAssociation-ClassificationNNP
r21amAUXprofessionalNN

#Rule:PPinNP
r26ClassificationNNofINChronic Heart FailureStageDescriptionAHigh riskOrganizationAnnotation
r26historyNNofINMINNS
r26symptomsNNSatINrestNN
r26restNNdespiteINtherapyPleaseNN
r26Association-ClassificationNNPofINHeart FOrganizationAnnotation

#Rule:V-IN-V
r43noteVBthatINamAUX

#Rule:V-ADV
r46seeVBPalsoRB
r46amAUXnotRB

@lemmas-left	LV	failureHypertension	Cardiac	inhibitors	developed	Diuretics	failuremarked	aldosterone	antagonist	physician	Classification	MI	American Heart Association	these	heart	patients.	prevent	failurestructural	include	3	present	2	urged	end-stage	1	urge	hypertension	coronary	syndrome	impair	therapyPlease	Stage	symptom	diseasecsymptomatic	diabetes	use	recommended	symptomatic	symptoms.	ACE	advised	patient	patients	life	failureStructural	consider	American College of Cardiology	depending	artery	note	mi	toleranceDRefractory	impaired	cases	refractory	ACC/AHA	toxin	remodel	valvular	Table1 New York Heart Association	cardiomyopathybasymptomatic	i	history	symptoms	including	cardiac	maximal	classification	base	failureprevious	high-tech	present.	inhibitor	based	acc/aha	familial	individual	transplantation	CAD	structural	antagonists	fatigue	medical	cardiomyopathyBAsymptomatic	family	Merck	care	developing	remodeling	be	such	cardiomyopathy.	select	beta-blockers	professional	therapies	Strategies	failure	failurePrevious	Chronic Heart FailureStageDescriptionAHigh risk	rest	case	therapy	ventricular	dysfunction	have	exercise	tolerancedrefractory	includes	disease	add	recommend	blocker	stage	diseaseCSymptomatic	considered	risk	selected	therapyplease	Physicians	advised.	develop	severe	toxins	added	depend	failurehypertension	strategy	cardiomyopathy	mellitus	severity	ace	stages	see	Heart F	Association-Classification	am	end-of-life	digoxin	resynchronization	dyspnea	
@lemmas-right	failureHypertension	inhibitors	developed	transplantation	antagonists	antagonist	Classification	MI	remodeling	be	heart	prevent	beta-blockers	professional	therapies	Strategies	include	not	present	failure	hypertension	Chronic Heart FailureStageDescriptionAHigh risk	syndrome	rest	case	therapyPlease	Stage	therapy	symptom	dysfunction	use	exercise	includes	disease	stage	blocker	symptoms.	risk	patient	patients	therapyplease	consider	develop	note	mi	cases	toxins	toxin	remodel	failurehypertension	strategy	mellitus	stages	history	symptoms	Heart F	see	Association-Classification	am	classification	present.	digoxin	inhibitor	also	
@lemmas-center	to	that	of	with	at	as	on	in	despite	